COMMUNIQUÉ DE PRESSE
News
-
-
COMMUNIQUÉ DE PRESSE
Moderna Reports Second Quarter 2024 Financial Results and Provides Business Updates
Moderna, Inc. reports Q2 revenues of $241 million, GAAP net loss of $1.3 billion. Updates 2024 financial framework and expects product sales of $3.0-$3.5 billion. Announces key developments in vaccines and financial results -
COMMUNIQUÉ DE PRESSE
Zomedica to Report Second Quarter 2024 Financial Results and Provide Business Update on August 14 at 4:30 p.m. ET
Zomedica Corp. to host a conference call on August 14, 2024, at 4:30 p.m. ET to discuss Q2 2024 financial results. The company provides veterinary health products for animals -
COMMUNIQUÉ DE PRESSE
"NanoViricides Broad Spectrum Technology Represents Potential Paradigm Shift In Viral Therapy"; "Novel Anti-Viral Could Boost a US$3 Billion Market" - Conclude Two Independent Research Reports on NanoViricides
NanoViricides, Inc., reports on independent research highlighting NV-387's broad-spectrum action in viral therapy, potentially revolutionizing antiviral treatment strategies -
-
-
COMMUNIQUÉ DE PRESSE
SUN.io Launches SUN DAO to Enhance Decentralized Governance and Drive Ecosystem Innovation
SUN.io launches SUN DAO, a decentralized governance initiative on TRON blockchain, enhancing community autonomy and protocol governance. SUN DAO to revolutionize DeFi governance, incentivizing active participation and innovation -
-
-
COMMUNIQUÉ DE PRESSE
MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory
MindBio Therapeutics appoints Haywood Securities Inc. as strategic advisor to support investment initiatives. Company progressing with Phase 2B clinical trials for psychedelic medicine MB22001
